Thelansis

  Head and Neck Squamous Cell Carcinoma (HNSCC) presents a multifaceted array of malignancies, creating formidable challenges for medical practitioners. The majority of patients receive diagnoses at an advanced local disease stage, necessitating treatment regimens that encompass surgery, chemotherapy, and radiotherapy. Regrettably, approximately 50% of these individuals will undergo disease recurrence. In cases of recurrent or metastatic HNSCC, the prognosis is notably grim, with a median survival rate ranging from 12 to 15 months despite treatment efforts. Head and neck cancer stands as the seventh most prevalent cancer globally, constituting 3% of all cancer cases, with an annual incidence of roughly 900,000 new cases and half a million fatalities. Human papillomavirus (HPV) infection is now recognized as the primary causative factor for HNSCC, particularly in the oropharynx (OPSCC), responsible for approximately 60-70% of OPSCC cases in the United States. HPV-positive (HPV+) H...